Pharmaceutical - Asia-Pacific, Eli Lilly

Filter

Current filters:

Asia-PacificEli Lilly

Popular Filters

India’s patents moves could see particular uncertainty for diabetes sector

India’s patents moves could see particular uncertainty for diabetes sector

17-02-2014

The Indian government's decision to review patented drugs by multinationals, to allow for the manufacture…

Abbott LaboratoriesAsia-PacificDiabetesEli LillyIndiaMarkets & MarketingMerck & CoNovo NordiskPatentsPharmaceutical

New Zealand views access to sugammadex and atomoxetine and baclofen injection funding

02-12-2013

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on the following proposals…

Asia-PacificBridionEli LillyLioresal IntrathecalMerck & CoNeurologicalNew ZealandPharmaceuticalRegulationStrattera

Trajenta studies prove efficacy in broad range of diabetes patients

Trajenta studies prove efficacy in broad range of diabetes patients

07-11-2013

Boehringer Ingelheim and Eli Lilly (NYSE: LLY) have released new data that reinforces the efficacy and…

Asia-PacificBoehringer IngelheimDiabetesEli LillyNorth AmericaPharmaceuticalResearchTrajentaUSA

Cardiovascular risk a concern when prescribing diabetes treatments, survey finds

06-11-2013

Boehringer Ingelheim and Eli Lilly (NYSE: LLY) revealed that 79% of nearly 800 physicians in four Asian…

Asia-PacificBoehringer IngelheimDiabetesEli LillyHealthcarePharmaceuticalResearch

Through 2022, growth in the neuropathic pain drug market will be constrained by generics

05-11-2013

The loss of US and European market exclusivity of three sales-leading neuropathic pain (NP) agents -…

Asia-PacificCymbaltaEli LillyEndo PharmaceuticalsEuropeLidodermLyricaMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceutical

Lilly acquires rights to Hutchison MediPharma cancer drug candidate

Lilly acquires rights to Hutchison MediPharma cancer drug candidate

09-10-2013

Hutchison MediPharma, an R&D company majority owned by China’s Chi-Med, has entered into a licensing,…

Asia-PacificEli LillyfruquintinibHutchison MediPharmaLicensingOncologyPharmaceutical

Eli Lilly latest to become embroiled in China bribery allegations

23-08-2013

In the ongoing allegations of bribery and corruption by multinational drugmakers in China, US pharma…

Asia-PacificEli LillyLegalMarkets & MarketingPharmaceutical

Daiichi Sankyo files for Japanese approval of Prasugrel

18-06-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) says that it has submitted a New Drug Application to the…

Asia-PacificCardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalprasugrelRegulation

Chinese diabetes market worth $2.2 billion, with over 50% accounted for by insulin

24-01-2013

Demand within the Chinese insulin market has grown at a fast pace in the past decade. Over the next five…

Asia-PacificDiabetesEli LillyMarkets & MarketingNovo NordiskPharmaceuticalSanofi

Nexavar use in Chinese patients nearly doubled in 2012

19-12-2012

Use of Nexavar (sorafenib, from Bayer [BAYN: DE] and Onyx Pharmaceuticals) has nearly doubled in first-line…

AlimtaAsia-PacificBayerBiotechnologyEli LillyMarkets & MarketingNexavarOncologyPharmaceutical

Eli Lilly and Chugai to stop co-marketing of Evista in Japan

05-11-2012

The Japanese subsidiary of US drug major Eli Lilly (NYSE: LLY) and Roche's (ROG: SIX) majority-owned…

Anti-Arthritics/RheumaticsAsia-PacificChugai PharmaceuticalEli LillyEvistaLicensingMarkets & MarketingPharmaceutical

Lilly to increase equity position in China's Novast by $20 million

13-06-2012

US pharma major Eli Lilly (NYSE: LLY) says it will increase of its network of manufacturing capabilities…

Asia-PacificEli LillyGenericsMergers & AcquisitionsNovast LaboratoriesPharmaceutical

New Zealand approves Effient listing for clopidogrel-allergic patients

19-03-2012

The Pharmaceutical Management Agency of New Zealand, PHARMAC, has announced reaching agreement with US…

Asia-PacificCardio-vascularEffientEli LillyPharmaceuticalPricingRegulation

Proposal to fund Lilly’s Effient in New Zealand

21-02-2012

PHARMAC, the Pharmaceutical Management Agency of New Zealand, is seeking feedback on a proposal to fund…

Asia-PacificEffientEli LillyPharmaceuticalPricingRegulation

ShangPharma milestone in Hengrui accord; expands Lilly contract

23-01-2012

Leading Chinese R&D outsourcing firm ShangPharma Corp (NYSE: SHP) says that it has reached the first…

Asia-PacificEli LillyJiangsu Hengrui MedicinePharmaceuticalResearchShangPharma

Back to top